A citation-based method for searching scientific literature

R E Ratner, R Dickey, M Fineman, D G Maggs, L Shen, S A Strobel, C Weyer, O G Kolterman. Diabet. Med. 2004
Times Cited: 151







List of co-cited articles
1310 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
Fred Whitehouse, Davida F Kruger, Mark Fineman, Larry Shen, James A Ruggles, David G Maggs, Christian Weyer, Orville G Kolterman. Diabetes Care 2002
157
50

A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.
Steve Edelman, Satish Garg, Juan Frias, David Maggs, Yan Wang, Bei Zhang, Susan Strobel, Karen Lutz, Orville Kolterman. Diabetes Care 2006
88
56

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.
Priscilla A Hollander, Philip Levy, Mark S Fineman, David G Maggs, Larry Z Shen, Susan A Strobel, Christian Weyer, Orville G Kolterman. Diabetes Care 2003
180
33

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
D M Nathan, S Genuth, J Lachin, P Cleary, O Crofford, M Davis, L Rand, C Siebert. N. Engl. J. Med. 1993
23

Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
Christian Weyer, Alan Gottlieb, Dennis D Kim, Karen Lutz, Sherwyn Schwartz, Maria Gutierrez, Yan Wang, James A Ruggles, Orville G Kolterman, David G Maggs. Diabetes Care 2003
56
35

Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.
Matthew Riddle, Juan Frias, Bei Zhang, Holly Maier, Carl Brown, Karen Lutz, Orville Kolterman. Diabetes Care 2007
62
30

Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes.
I Chapman, B Parker, S Doran, C Feinle-Bisset, J Wishart, S Strobel, Y Wang, C Burns, C Lush, C Weyer,[...]. Diabetologia 2005
116
18

The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.
M S Fineman, J E Koda, L Z Shen, S A Strobel, D G Maggs, C Weyer, O G Kolterman. Metab. Clin. Exp. 2002
76
22

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N. Engl. J. Med. 2017
139
16

The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.
B Nyholm, L Orskov, K Y Hove, C H Gravholt, N Møller, K G Alberti, C Moyses, O Kolterman, O Schmitz. Metab. Clin. Exp. 1999
69
21

Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes.
David G Marrero, John Crean, Bei Zhang, Terrie Kellmeyer, Maurice Gloster, Kathrin Herrmann, Richard Rubin, Naomi Fineberg, Orville Kolterman. Diabetes Care 2007
29
51

Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.
Robert E Ratner, Laura L Want, Mark S Fineman, Maggie J Velte, James A Ruggles, Alan Gottlieb, Christian Weyer, Orville G Kolterman. Diabetes Technol. Ther. 2002
97
15

Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
Chantal Mathieu, Bernard Zinman, Joanna Uddén Hemmingsson, Vincent Woo, Peter Colman, Erik Christiansen, Martin Linder, Bruce Bode. Diabetes Care 2016
72
20

Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets.
R Ratner, F Whitehouse, M S Fineman, S Strobel, L Shen, D G Maggs, O G Kolterman, C Weyer. Exp. Clin. Endocrinol. Diabetes 2005
33
42


The use of metformin in type 1 diabetes: a systematic review of efficacy.
S Vella, L Buetow, P Royle, S Livingstone, H M Colhoun, J R Petrie. Diabetologia 2010
100
14

Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
David M Nathan, Patricia A Cleary, Jye-Yu C Backlund, Saul M Genuth, John M Lachin, Trevor J Orchard, Philip Raskin, Bernard Zinman. N. Engl. J. Med. 2005
14


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N. Engl. J. Med. 2015
14

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.
John R Petrie, Nishi Chaturvedi, Ian Ford, Martijn C G J Brouwers, Nicola Greenlaw, Therese Tillin, Irene Hramiak, Alun D Hughes, Alicia J Jenkins, Barbara E K Klein,[...]. Lancet Diabetes Endocrinol 2017
91
15

Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients.
G J Cooper, A C Willis, A Clark, R C Turner, R B Sim, K B Reid. Proc. Natl. Acad. Sci. U.S.A. 1987
780
13

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
David M Kendall, Matthew C Riddle, Julio Rosenstock, Dongliang Zhuang, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
779
13

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
Ralph A DeFronzo, Robert E Ratner, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
950
13

Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity.
Steve R Smith, Louis J Aronne, Colleen M Burns, Nicole C Kesty, Amy E Halseth, Christian Weyer. Diabetes Care 2008
82
15

Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study.
Louis Aronne, Ken Fujioka, Vanita Aroda, Kim Chen, Amy Halseth, Nicole C Kesty, Colleen Burns, Cameron W Lush, Christian Weyer. J. Clin. Endocrinol. Metab. 2007
86
15

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
113
13

Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition.
M Samsom, L A Szarka, M Camilleri, A Vella, A R Zinsmeister, R A Rizza. Am. J. Physiol. Gastrointest. Liver Physiol. 2000
78
15

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
William C Knowler, Elizabeth Barrett-Connor, Sarah E Fowler, Richard F Hamman, John M Lachin, Elizabeth A Walker, David M Nathan. N. Engl. J. Med. 2002
12

Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study.
Søren Søgaard Lund, Lise Tarnow, Anne Sofie Astrup, Peter Hovind, Peter Karl Jacobsen, Amra Ciric Alibegovic, Ida Parving, Lotte Pietraszek, Merete Frandsen, Peter Rossing,[...]. PLoS ONE 2008
47
25


The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes.
Rubina A Heptulla, Luisa M Rodriguez, Lisa Bomgaars, Morey W Haymond. Diabetes 2005
54
20

Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.
Claresa Levetan, Laura L Want, Christian Weyer, Susan A Strobel, John Crean, Yan Wang, David G Maggs, Orville G Kolterman, Manju Chandran, Sunder R Mudaliar,[...]. Diabetes Care 2003
84
13

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
John B Buse, Robert R Henry, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2004
821
11

Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM.
M F Kong, P King, I A Macdonald, T A Stubbs, A C Perkins, P E Blackshaw, C Moyses, R B Tattersall. Diabetologia 1997
79
13

Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.
S L Ellis, E G Moser, J K Snell-Bergeon, A S Rodionova, R M Hazenfield, S K Garg. Diabet. Med. 2011
80
13


Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation.
P Westermark, U Engström, K H Johnson, G T Westermark, C Betsholtz. Proc. Natl. Acad. Sci. U.S.A. 1990
484
11

Amylin concentrations and glucose control.
J E Koda, M Fineman, T J Rink, G E Dailey, D B Muchmore, L G Linarelli. Lancet 1992
96
11

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
Arthur T Sands, Brian P Zambrowicz, Julio Rosenstock, Pablo Lapuerta, Bruce W Bode, Satish K Garg, John B Buse, Phillip Banks, Rubina Heptulla, Marc Rendell,[...]. Diabetes Care 2015
100
11

Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
Christian S Frandsen, Thomas F Dejgaard, Jens J Holst, Henrik U Andersen, Birger Thorsteinsson, Sten Madsbad. Diabetes Care 2015
43
25

Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Thomas Fremming Dejgaard, Christian Seerup Frandsen, Tanja Stenbæk Hansen, Thomas Almdal, Søren Urhammer, Ulrik Pedersen-Bjergaard, Tonny Jensen, Andreas Kryger Jensen, Jens Juul Holst, Lise Tarnow,[...]. Lancet Diabetes Endocrinol 2016
52
21

Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.
Kellee M Miller, Nicole C Foster, Roy W Beck, Richard M Bergenstal, Stephanie N DuBose, Linda A DiMeglio, David M Maahs, William V Tamborlane. Diabetes Care 2015
619
11

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
Bo Ahrén, Irl B Hirsch, Thomas R Pieber, Chantal Mathieu, Fernando Gómez-Peralta, Troels Krarup Hansen, Areti Philotheou, Sune Birch, Erik Christiansen, Thomas Jon Jensen,[...]. Diabetes Care 2016
49
22


Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes.
Matthew Riddle, Richard Pencek, Supoat Charenkavanich, Karen Lutz, Ken Wilhelm, Lisa Porter. Diabetes Care 2009
38
26

Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies.
Jonathan D Roth, Barbara L Roland, Rebecca L Cole, James L Trevaskis, Christian Weyer, Joy E Koda, Christen M Anderson, David G Parkes, Alain D Baron. Proc. Natl. Acad. Sci. U.S.A. 2008
256
10

10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N. Engl. J. Med. 2008
10

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Robert R Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List, Steven C Griffen. Diabetes Care 2015
131
10

Temporal patterns in overweight and obesity in Type 1 diabetes.
B Conway, R G Miller, T Costacou, L Fried, S Kelsey, R W Evans, T J Orchard. Diabet. Med. 2010
145
10

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
T R Pieber, S Famulla, J Eilbracht, J Cescutti, N Soleymanlou, O E Johansen, H J Woerle, U C Broedl, S Kaspers. Diabetes Obes Metab 2015
84
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.